Non-Small Cell Lung Cancer Pipeline Analysis: 135+ Companies are Working to Improve the Treatment Space | DelveInsight

 Breaking News
  • No posts were found

Non-Small Cell Lung Cancer Pipeline Analysis: 135+ Companies are Working to Improve the Treatment Space | DelveInsight

October 12
21:23 2022
Non-Small Cell Lung Cancer Pipeline Analysis: 135+ Companies are Working to Improve the Treatment Space | DelveInsight

DelveInsight’s, Non-Small-Cell Lung cancer Pipeline Insight, 2022,” report provides comprehensive insights about 135+ companies and 150+ pipeline drugs in the Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Non-Small Cell Lung Cancer Pipeline Report

  • DelveInsight’s Non-Small Cell Lung Cancer Pipeline report depicts a robust space with 135+ active players working to develop 150+ pipeline therapies for Non-Small Cell Lung Cancer treatment.
  • The leading Non-Small Lung Cancer Companies includes BridgeBio Pharma, Daiichi Sankyo, EMD Serono/Merck, BridgeBio Pharma, Abbvie/Pfizer, Eli Lilly and Company, BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical/Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, and others are developing potential drug candidates to improve the Non-Small Cell Lung Cancer treatment scenario.
  • The promising Non-Small Cell Lung Cancer therapies in the pipeline includes DS-1062a, M7824, Sulijia, ONO-4538, eribulin mesylate, Exisulind, and others.
  • JDQ443, an investigational selective, covalent, and orally bioavailable KRASG12C inhibitor, shows 57% confirmed ORR at recommended dose of 200 mg twice daily in Phase Ib study in patients with advanced non-small cell lung cancer (NSCLC).
  • INBRX-106 is a hexavalent product candidate agonist of OX40. OX40 is a co-stimulatory receptor expressed on immune cells that is enriched in the tumor microenvironment. OX40 ligand is a trimeric protein that activates OX40 signaling through clustering.  INBRX-106 was engineered to bind and cluster six OX40 receptors and has been shown preclinically to significantly outperform bivalent antibodies in co-stimulatory capacity and anti-tumor activity.

 

Get an overview of the Non-Small Cell Lung Cancer Pipeline landscape @ Non-Small Cell Lung Cancer Pipeline Outlook

 

Non-Small Cell Lung Cancer Overview

Non-small-cell lung cancer (NSCLC) is any type of epithelial lung cancer other than small-cell lung cancer (SCLC) and accounts for about 85% of all lung cancers. There are three kinds of NSCLC tumors: a) Adenocancer starts in cells inside air sacs that make mucus and other substances, often in the outer parts of your lungs. It’s the most common kind of lung cancer among both smokers and nonsmokers and people under 45. It often grows more slowly than other lung cancers. b) Squamous cell lung cancer starts in cells that line the inner airways of the lungs. About a quarter of lung cancers are this kind. c) Large cell (undifferentiated) cancer grows and spreads more quickly. That can make it tougher to treat. It’s about 10% of lung cancers. An effective treatment for non-small cell adenocancer depends on the cancer’s stage. Surgery to remove all or only part of the lung is usually required if the cancer hasn’t spread.

 

Latest Breakthroughs and Developments in the Non-Small Cell Lung Cancer Treatment Landscape

  • Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2 directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, datopotamab deruxtecan is one of three leading ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programs in AstraZeneca’s ADC scientific platform. Datopotamab deruxtecan is comprised of a humanized anti-TROP2 IgG13 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor payloads, an exatecan derivative, via tetrapeptide-based cleavable linkers.
  • JNJ-6372 and TAK-788 are mainly targeting EGFR exon 20 insertion mutations are also expected to generate good revenue in the coming years.
  • Adagrasib (MRTX849) is an investigational, highly selective, and potent oral small-molecule inhibitor of KRASG12C that is optimized to sustain target inhibition, an attribute that could be important to treat KRASG12C-mutated cancers, as the KRASG12C protein regenerates every 24–48 hours. Adagrasib is being evaluated as monotherapy and in combination with other anti-cancer therapies in patients with advanced KRASG12C-mutated solid tumors, including NSCLC, colorectal cancer and pancreatic cancer.

 

Non-Small Cell Lung Cancer Emerging Drugs

  • Datopotamab deruxtecan: Daiichi Sankyo
  • JDQ443: Novartis
  • MRTX849: Mirati Therapeutics
  • INBRX-106: Inhibrx

 

Get to know more information about Non-Small Cell Lung Cancer Treatment therapies @ Non-Small Cell Lung Cancer Clinical Trials

 

Non-Small Cell Lung Cancer Pipeline Therapeutics Analysis

There are approx. 135+ key companies which are developing the therapies for Non-Small-Cell Lung cancer (NSCLC). The companies which have their Non-Small-Cell Lung cancer (NSCLC) drug candidates in the most advanced stage, i.e. Phase III include Daiichi Sankyo.

 

DelveInsight’s Non-Small Cell Lung Cancer Pipeline Report covers around 150+ products under different phases of clinical development like-

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Discover more about therapy set to grab substantial Non-Small Cell Lung Cancer Pipeline landscape @ Non-Small Cell Lung Cancer Market Drivers and Barriers

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Non-Small-Cell Lung cancer (NSCLC) drugs?
  • How many Non-Small-Cell Lung cancer (NSCLC) drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Non-Small-Cell Lung cancer (NSCLC)?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Non-Small-Cell Lung cancer (NSCLC) therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Non-Small-Cell Lung cancer (NSCLC) and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Scope of the Non-Small Cell Lung Cancer Pipeline Report

  • Coverage- Global
  • Non-Small Cell Lung Cancer Companies– BridgeBio Pharma, Daiichi Sankyo, EMD Serono/Merck, BridgeBio Pharma, Abbvie/Pfizer, Eli Lilly and Company, BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical/Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, and others
  • Non-Small Cell Lung Cancer Therapies– DS-1062a, M7824, Sulijia, ONO-4538, eribulin mesylate, Exisulind, and others
  • Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type
  • Non-Small Cell Lung Cancer Therapeutic Assessment by Stage and Product Type
  • Non-Small Cell Lung Cancer Therapeutic Assessment by Route of Administration
  • Non-Small Cell Lung Cancer Therapeutic Assessment by Stage and Route of Administration
  • Non-Small Cell Lung Cancer Therapeutic Assessment by Molecule Type
  • Non-Small Cell Lung Cancer Therapeutic Assessment by Stage and Molecule Type
  • Non-Small Cell Lung Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
  • Non-Small Cell Lung Cancer – Market Drivers and Barriers

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Non-Small-Cell Lung cancer (NSCLC): Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Non-Small-Cell Lung cancer (NSCLC)– DelveInsight’s Analytical Perspective
  7. Mid Stage Products (Phase III)
  8. Datopotamab deruxtecan: Daiichi Sankyo
  9. Mid Stage Products (Phase II)
  10. RMC-4630: REVOLUTION Medicines
  11. Early Stage Products (Phase I/II)
  12. GB 1211: BridgeBio Pharma
  13. Early Stage Products (Phase I)
  14. BBP 398: BridgeBio Pharma.
  15. Preclinical Stage Products
  16. Drug name: Company name
  17. Inactive Products
  18. Non-Small-Cell Lung cancer (NSCLC) Key Companies
  19. Non-Small-Cell Lung cancer (NSCLC) Key Products
  20. Non-Small-Cell Lung cancer (NSCLC)- Unmet Needs
  21. Non-Small-Cell Lung cancer (NSCLC)- Market Drivers and Barriers
  22. Non-Small-Cell Lung cancer (NSCLC)- Future Perspectives and Conclusion
  23. Non-Small-Cell Lung cancer (NSCLC) Analyst Views
  24. Non-Small-Cell Lung cancer (NSCLC) Key Companies
  25. Appendix

 

Got Queries? Reach out for more information on the Non-Small-Cell Lung cancer Pipeline Report- Non-Small-Cell Lung cancer Pipeline Therapeutic Assessment

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Categories